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Despite high leptin levels, most obese humans
and rodents lack responsiveness to its appe-
tite-suppressing effects. We demonstrate that
leptin modulates NPY/AgRP and a-MSH secre-
tion from the ARH of lean mice. High-fat diet-
induced obese (DIO) mice have normal ObRb
levels and increased SOCS-3 levels, but leptin
fails to modulate peptide secretion and any ele-
ment of the leptin signaling cascade. Despite
this leptin resistance, the melanocortin system
downstream of the ARH in DIO mice is over-
responsive to melanocortin agonists, probably
due to upregulation of MC4R. Lastly, we show
that by decreasing the fat content of the
mouse’s diet, leptin responsiveness of NPY/
AgRP and POMC neurons recovered simulta-
neously, with mice regaining normal leptin sen-
sitivity and glycemic control. These results
highlight the physiological importance of leptin
sensing in the melanocortin circuits and show
that their loss of leptin sensing likely contrib-
utes to the pathology of leptin resistance.
INTRODUCTION
Obesity is defined as an excessive amount of body fat in
relation to lean mass of sufficient magnitude to produce
adverse health consequences. More than 60% of Ameri-
can adults are now overweight or obese, and the obesity
prevalence in adults and children is growing dramatically
(Zamboni et al., 2005). In most adults, body weight is rel-
atively constant despite large variations in daily food in-
take and energy expenditure. Energy balance is regulated
by neural and hormonal signals that are integrated in the
brain (Seeley and Woods, 2003). Leptin, a hormone se-
creted primarily by adipocytes, is present in serum con-
centrations directly proportional to the amount of adiposeCetissue (Considine et al., 1996), signaling to the central ner-
vous system (CNS) the relative extent of energy (adipose)
stores in the body (Spiegelman and Flier, 2001).
Leptin regulates food intake by binding to CNS recep-
tors and modulating the activity of neurons in appetite
control centers in the brain (de Luca et al., 2005). In obese
leptin-deficient mice, administration of leptin reduces hy-
perphagia and obesity. In contrast, obese mice that are
deficient in the leptin receptor (ObRb) do not respond to
leptin (Chen et al., 1996; Halaas et al., 1995). Leptin also
affects energy expenditure in rodents and humans (Halaas
et al., 1995; Rosenbaum et al., 2005). Activation of central
ObRb increases sympathetic nervous system activity,
which stimulates energy expenditure in adipose tissue
(Commins et al., 1999).
The arcuate nucleus in the hypothalamus (ARH) is a
major site of leptin sensing (Balthasar et al., 2004; Coppari
et al., 2005; Cowley et al., 2001; van den Top et al., 2004).
ObRb is highly expressed in the ARH (Elmquist et al.,
1998; Schwartz et al., 1996). To access these receptors,
peripheral leptin is transported across the blood-brain
barrier to reach areas distal to circumventricular organs
(Banks, 2003).
The ARH contains at least two key populations of leptin-
responsive neurons that have opposite actions on food in-
take. One population expresses the anorexigenic peptide
a-melanocyte-stimulating hormone (a-MSH), derived from
the proopiomelanocortin (POMC) precursor. The other
population expresses the orexigenic peptides, neuropep-
tide Y (NPY) and agouti-related peptide (AgRP) (Cone,
2005). Arcuate neurons subsequently innervate various
second-order hypothalamic targets that express melano-
cortin-4 receptors (MC4R) and NPY receptors (Liu et al.,
2003). Leptin can modulate both POMC and AgRP neu-
rons and can promote the release of a-MSH, a potent ano-
rexigen at central MC4Rs (Cowley et al., 2001; Elias et al.,
1999; Schwartz et al., 1997).
Although most obese humans and rodents have very
high amounts of circulating leptin, this hyperleptinemia
neither reduces appetite nor increases energy expendi-
ture. This state has been termed ‘‘leptin resistance.’’ Therell Metabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 181
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ble for obesity in humans, and the majority of ‘‘normal’’
obesity is thought to be a consequence of polygenic inter-
action with the environment (Tschop and Heiman, 2001).
Two hypotheses proposing mechanistic explanations for
leptin resistance have received considerable attention:
(1) failure of circulating leptin to reach its central targets
(Banks, 2003); and (2) failure within components of the in-
tracellular ObRb signaling cascade (Munzberg andMyers,
2005).
Mouse models of dietary obesity provide an excellent
system to identify how leptin signaling becomes compro-
mised when leptin resistance occurs. C57BL/6J mice fed
a high-fat diet (HFD) exhibit increased body adiposity
along with other characteristics of human obesity, such
as diabetes mellitus (>70% of mice on HFD) (Burcelin
et al., 2002). Notably, mice on HFD lose weight when the
fat content of the diet decreases, independent of total cal-
orie intake (Parekh et al., 1998). The development of obe-
sity and leptin resistance in C57BL/6Jmice onHFD can be
divided into three stages. In the early stage, mice gain
weight (adiposity) but maintain an adequate response to
anorectic effects of peripheral leptin injection. In the mid-
dle stage, mice lose peripheral leptin sensitivity while re-
taining the capacity to respond to central leptin. Finally,
in the late stage, mice demonstrate central leptin resis-
tance (El-Haschimi et al., 2000).
Recently, it was shown that the expression of pStat3
(signal transducer and activator of transcription) in arcuate
neurons was selectively reduced in leptin-treated diet-in-
duced obese (DIO) mice but not in neurons within the
VMH or DMH, suggesting that the ARH is a major site of
leptin resistance. It was proposed that the increase of sup-
pressor of cytokine signaling-3 (SOCS-3) levels may
cause defective leptin signaling in the ARH of HFD mice
(Munzberg et al., 2004). The heterozygous SOCS-3-defi-
cient mouse was more sensitive to the weight-reducing
effects of leptin and was resistant to the development of
DIO (Howard et al., 2004). Moreover, using a SOCS-3
deficient (within the brain) mouse, Mori et al. showed
that the level of POMC induced by leptin was greater in
SOCS-3 deficient mice than in wild-type mice (Mori et al.,
2004). These data indicate that SOCS-3 is a negative
regulator of leptin-induced pStat3 signaling in the hypo-
thalamus and that excessive activity of SOCS-3 may be
a potential mechanism for leptin resistance.
We hypothesized that leptin sensitivity of POMC and
NPY/AgRP neurons in the ARH is altered in male mice
fed HFD. If so, we intended to explore the molecular
mechanisms involved. Lastly, we wanted to determine if
altered sensitivity could be restored when DIO mice lose
weight after decreasing the fat content of their diet.
RESULTS
Effects of HFD on Body Composition: Body Weight,
Fat Tissue, and Leptin Levels
At 20 weeks, mice fed HFD had a wide distribution in body
weight gain showing bimodal characteristics. The heavier182 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier Incgroup on the HFD was named ‘‘diet-induced obese’’ (DIO)
mice. Others on HFD remained almost as lean as controls,
those fed regular chow (Figure 1A). We defined these as
‘‘diet-induced obese resistant’’ (DIO-R) mice, those with
body weights ranging between the average ± 3 standard
deviations of the control group. The small number of
mice (5%) that overlapped in the bimodal distribution
of body weight was excluded from experiments. The fre-
quency of DIO-R and DIO per cage was normally distrib-
uted, and the same ratio occurred when the mice were
individually housed. Interestingly, initial body weight of
identically aged mice significantly correlated to final
weight and was the only factor that predicted DIO-R ver-
sus DIO (Figure S1 in the Supplemental Data available
with this article online). No pre-existing differences to lep-
tin sensitivity were seen between highest- and lowest-
weight mice preceding HFD exposure; weight loss and
decrease in food intake was similar with i.p. leptin (data
not shown).
Over a period of 20 weeks, the DIO-R group became
only 6.7% heavier than the control group, while the DIO
group became 32.9% heavier (Figure 1B). The number of
mice that became obese on the HFD steadily increased
over time. By 13–15 weeks on HFD, 65% of mice had
become obese and this percentage remained stable past
20 weeks. At this point, the lean mass gain was similar for
every group (control 6.7 ± 2.1 g, DIO-R 6.1 ± 1.1 g, DIO
8.0 ± 1.5 g). In contrast, fat gain was significantly different
among the three groups. Control mice gained 1.7 g of fat
and DIO-Rmice gained 4.5 g of fat, (p < 0.001). The largest
fat gain was obtained by the DIO group (10.5 g), around
five times that of the control fat gain (p < 0.001). Thus, the
extra weight gain in mice fed HFD was mostly due to
accumulation of body fat. In parallel, leptin levels were
elevated by 20weeks onHFD andwere significantly differ-
ent between every group (control 3.7 ± 2.0 ng/ml, n = 64;
DIO-R 14.3 ± 9.1 ng/ml, n = 56 and DIO 36.7 ± 10.0 ng/ml,
n = 58, p < 0.001).
Effects of HFD on Food Intake
In DIO-Rmice, calorie intake increased and paralleled that
of control for the first 4 weeks; then, calorie intake de-
creased significantly from the fifth week until the end of
the experiment. Although calorie intake in DIO mice was
no different from the control, because of the different mac-
ronutrient composition of the diets, they were consuming
significantly more fat (Figure 1C). Thus, obesity in C57BL/
6J mice fed a HFD is not a result of hyperphagia but in-
creased feeding efficiency (weight gained/kcal con-
sumed) (Figure 1D).
Peripheral Leptin Effect on Food Intake and
Body Weight after 20 weeks on HFD
We determined the minimum dose that could modify body
weight or food intake in control mice (2 mg/g body weight
for 2 days). After the second day of leptin injection, the
control and DIO-R mice significantly lost weight. In con-
trast, the DIO group did not show any change in body
weight (Figure 2A). Calorie intake after leptin treatment.
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Leptin Resistance in Arcuate Melanocortin NeuronsFigure 1. Body Weights and Feeding Characteristics for Mice Fed Regular Chow versus Mice Fed HFD
(A) Body weight distribution of control (12% fat diet) and DIO-R/DIO (45% fat diet) mice after 20 weeks. Normality test (DIO-R/DIO) was p < 0.0001.
(B) Body weight change of control, DIO-R, and DIO mice over 20 weeks. Results expressed as mean ± SEM (*p < 0.001).
(C) Total calorie, total fat, total protein, and total carbohydrate calorie intake for control, DIO-R, and DIO groups after 20 weeks.
(D) Feed efficiency (weight gained/kcal consumed) of control, DIO-R, and DIO groups.
Results expressed as mean ± SEM (*p < 0.001).was reduced significantly in the control and DIO-R mice.
However, no significant difference was found in the
DIO group (Figure 2B). Two hours after i.p. leptin, leptin
plasma concentrations in all groups were between 160–
190 ng/ml. This represented a 40-fold increase from
endogenous levels in control mice, a 12-fold increase in
DIO-R mice, and a 5-fold increase in DIO mice (p < 0.001).
Central Leptin Effect after 20 Weeks on HFD
After i.c.v. leptin, control and DIO–Rmice had a significant
reduction of body weight at 24 hr. However, the DIO group
showed no change (Figure 3C). Calorie intake after 24 hr
was reduced by20% in control and DIO-R mice. No sig-
nificant difference was found in the DIO group (Figure 2D).
To confirm this lack of i.c.v. leptin responsiveness, we
measured the immediate-early gene c-Fos (a marker of
neuronal activation) in the ARH. After i.c.v. leptin, c-Fos
expression significantly increased in control mice, but re-
mained unchanged in DIO mice (data not shown).
Hypothalamic Secretion Experiment
after 20 or 37 Weeks on HFD
We studied the baseline secretion of AgRP, NPY, and a-
MSH from hypothalamic blocks. There was no differenceCellin the baseline, nonstimulated secretion of NPY, AgRP,
or a-MSH in DIO-R mice or DIO mice when compared
with controls (Figure S2). Incubation with leptin caused
a dose-dependent inhibition of AgRP and NPY secretion
in the control group (EC50 = 23 nM, EC50 = 17 nM, re-
spectively). The DIO-R group showed similar curves and
similar EC50s (24 nM, 20 nM, respectively). On the con-
trary, AgRP and NPY secretion in the DIO group did not
change with an increase in leptin concentration (Figures
3A–3F). The sensitivity of POMC neurons to leptin was
studied by measuring a-MSH secretion. Incubation with
leptin caused a dose-dependent increase of a-MSH levels
in the control and DIO-R groups (EC50 = 46 nM, EC50 =
37 nM, respectively). The DIO group, however, was again
resistant to the effects of leptin (Figures 3G–3I). We
defined the a-MSH/AgRP secretion ratio as an index of
activation of the MC4R. DIO-R mice had a 3-fold higher
ratio of a-MSH to AgRP secretion than DIO mice
(Figure 3J).
Peripheral Leptin Effect on ARH mRNA Expression
after 20 Weeks on HFD
Since AgRP mRNA expression increases from rostral to
caudal within the ARH (Wilson et al., 1999), neuropeptideMetabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 183
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Leptin Resistance in Arcuate Melanocortin NeuronsFigure 2. Effect of Peripheral and Central Leptin on Body Weight and Calorie Intake in Control, DIO-R, and DIO Mice
(A) Body weight change (%) 24 hr after i.p. saline or leptin (2 mg/g/day).
(B) Calorie intake 2 days after i.p. leptin (2 mg/g/day). Data from each group were normalized to their own saline control.
(C) Body weight change (%) 24 hr after i.c.v. aCSF or leptin (0.1 mg).
(D) Calorie intake 1 day after i.c.v. leptin (0.1 mg). Data from each group were normalized to their own aCSF control.
Results expressed as mean ± SEM (**p < 0.01, ***p < 0.001).expression was divided into caudal and rostral regions
for analysis. After i.p. leptin, caudal levels of AgRP expres-
sion were decreased by 30% in both control and DIO-R
mice. In contrast, DIO mice showed no expression
changes (Figure 4A). Rostral areas of the ARH showed
no differences in AgRP levels after leptin. Baseline levels
of NPY expression were not significantly different between
control and DIO groups. After leptin injection, NPY mRNA
expression decreased 50% in control. There was no
change in NPY mRNA expression in the DIO group
(Figure 4B).
Neither baseline nor leptin-induced POMC mRNA ex-
pression was significantly different among groups when
we considered the entire extent of the ARH or just rostral
sections (Figure 4C). ObRb expression was not signifi-
cantly different among groups in baseline levels (Fig-
ure 4D) nor after leptin injection (data not shown).
Synthesis of POMC-Derived Peptides in ARH
In order to test if the obesity-resistant phenotype (DIO-R)
is due to a sustained level of anorexigenic POMC-derived
peptides, we measured ACTH, CLIP, acetyl, and desace-
tyl-a-MSH. Desacetyl-a-MSH levels in DIO and DIO-R
mice were significantly lower than control mice (Fig-
ure 4E). The same decrease of ACTH, CLIP, and acetyl
a-MSHwere also seen in DIO-R and DIOmice (Figure S2).184 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier InPeripheral Leptin Effect on ARH Signal Transduction
after 20 Weeks on HFD
In order to assess leptin-induced activation of ARH cells,
we measured c-Fos, phosphorylation of Stat3 (a well-
known mediator of leptin activation) and pMAPK (a mea-
sure of the MAP Kinase pathway activation) in leptin-
treated mice. Baseline conditions showed no significant
differences among groups in the number of cells express-
ing c-Fos, pStat3, or pMAPK. After i.p. leptin, c-Fos ex-
pression in control and DIO-R groups increased signifi-
cantly whereas there was no change in the DIO group
(Figure 5A). pStat3 expression was dramatically increased
in control and moderately elevated in the DIO-R leptin-
treated group. No change was observed in the DIO group
(Figure 5B). The control group showed a 2-fold increase in
the positive pMAPK cells after leptin, whereas the DIO-R
and DIO groups showed no difference (Figure 5C).
We measured SOCS-3 levels by ISH and real-time PCR
in the ARH. Although the ISH data were inconclusive, we
found higher levels of SOCS-3 mRNA in baseline condi-
tions of DIO mice using real-time PCR. After i.p. leptin,
control mice had elevated SOCS-3 levels while levels re-
mained unchanged in DIO mice (Figure 5D).
Integrity of the Melanocortin Pathway
The unresponsiveness to leptin in DIO mice may be due
to a primary insensitivity or a lack of secondary neuronalc.
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Leptin Resistance in Arcuate Melanocortin NeuronsFigure 3. Leptin Modulation of Hypothalamic Neuropeptide Secretion in Control, DIO-R, and DIO groups
Data from each group were normalized to baseline levels. Figures represent four independent experiments.
(A–C) Leptin modulation of AgRP secretion.
(D–F) Leptin modulation of NPY secretion.
(G–I) Leptin modulation of a-MSH secretion.
(J) The a-MSH/AgRP ratio of secretion.
Results expressed as mean ± SEM (p < 0.001).targets. The melanocortin pathway is a well-established
pathway that mediates leptin’s actions. We tested the
hypothesis that the melanocortin system downstream
of POMC neurons is intact by using a very low dose ofCellMTII, a potent melanocortin agonist. One hour after
i.p. MTII, calorie intake was reduced 45% in control,
65% in DIO-R, and 90% in DIO. The orexigenic effect
of MTII was maintained for 4 hr in control and DIO-RMetabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 185
Cell Metabolism
Leptin Resistance in Arcuate Melanocortin NeuronsFigure 4. mRNA Neuropeptide Expression after i.p. Leptin, Expression of ObRb mRNA, and Concentration of Desacetyl-a-MSH in
the ARH in Control, DIO-R, and DIO Groups
Results expressed as mean ± SEM (*p < 0.05, ***p < 0.001).
(A) Caudal AgRP mRNA expression after i.p. leptin (2 mg/g)/saline.
(B) Total NPY mRNA expression after i.p. leptin (2 mg/g)/saline.
(C) Total POMC mRNA expression after i.p. leptin (2 mg/g)/saline.
(D) Baseline ObRb expression.
(E) Desacetyl-a-MSH concentration.groups and continued over 8 hr in the DIO group
(Figure 6A).
When mice were given central MTII, they responded
similarly to the peripheral injection: DIO mice showed
a greater and prolonged response to MTII than control
or DIO-Rmice (data not shown). To determine if this exag-
gerated response in DIO mice was due to an upregulation
of MC4R mRNA expression, we measured the expression
in the PVH by ISH. Levels of MC4RmRNAwere very low in
control and DIO-R mice but were strikingly high in DIO
mice (Figure 6B). We did an additional analysis of this
gene expression by performing real-time PCR on micro-
dissected PVH samples. The MC4R expression was sig-
nificantly higher in DIOmice than in control mice (p < 0.05).
Restoration of Leptin Sensitivity after Changing
from HFD to Regular Chow
To determine whether the effects of a HFD on energy
balance were reversible, after 20 weeks on HFD, we con-186 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier Intinued one cohort of mice on HFD (DIO) and the other
cohort was returned to regular chow diet (restored). Re-
stored mice continuously lost weight and after 7 weeks
showed similar body weights to control (those maintained
on regular chow during the whole experiment) (Figure 7A).
Although total calorie intake of restored mice (weeks 20 to
37) was similar to that of DIO mice, total fat calorie intake
was 5 times lower in the restored group (p < 0.001).
After 20 weeks on HFD, DIOmice were intolerant to glu-
cose and insulin resistant. This intolerance and resistance
worsened by 37 weeks, causing more than 70% of the
mice to be diabetic. Mice were classified as diabetic
when glucose AUCwas 3 SD higher than themean of con-
trol mice (Burcelin et al., 2002). At the end of 37 weeks, the
restored group responded normally to glucose and insulin
challenges (Figure 7B). Thus, the diabetes/obesity syn-
drome appears reversible at this stage.
We determined the leptin sensitivity of the restored
group by injecting mice with leptin. After the second dayc.
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Leptin Resistance in Arcuate Melanocortin NeuronsFigure 5. Effect of i.p. Leptin on Signal Transduction in the ARH
Results expressed as mean ± SEM. Representative microphotographs of hypothalamic sections are shown from control, DIO-R, and DIO groups
(*p < 0.05, **p < 0.01, ***p < 0.001, ##p < 0.01 saline control versus saline DIO).
(A) Expression of c-Fos 30 min after i.p. leptin (2 mg/g)/saline.
(B) Expression of pStat3 30 min after i.p. leptin (2 mg/g)/saline.
(C) Expression of pMAPK 30 min after i.p. leptin (2 mg/g)/saline.
(D) Expression of SOCS-3 mRNA 45 min after i.p. saline (2 mg/g)/leptin.of i.p. leptin, body weight of the restored group was signif-
icantly reduced. This was identical to the sensitivity of the
control group (Figure 7C). In addition, 100 nM leptin in-
hibited secretion of AgRP and NPY and stimulated secre-
tion of a-MSH from hypothalamic explants in restoredCellmice. In contrast, leptin did not modulate the secretion of
AgRP, NPY, nor a-MSH from hypothalami of DIO mice (at
37 weeks) (Figures 7D, 7E, and 7F). These results show
that sensitivity to leptin in the ARH was re-established
in the restored group.Metabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 187
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(A) Effect of i.p. MTII (1 mg/g) over 24 hr on food
intake in control, DIO-R, and DIO groups. Data
from each group normalized to their own saline
control.
(B) Representative microphotograph and re-
sults of baseline MC4R mRNA expression in
PVH of control, DIO-R, and DIO groups.
Results expressed as mean ± SEM (***p <
0.001).DISCUSSION
Using a unique hypothalamic explant secretion assay,
we demonstrate that leptin modulates NPY/AgRP and
a-MSH secretion from the ARH in mice fed regular chow
(control) and mice that remain lean when fed HFD
(DIO-R). Leptin stimulated a-MSH secretion and inhibited
NPY/AgRP secretion in a dose-dependent manner. On
the contrary, leptin failed to modulate the secretion of
melanocortin peptides in obese mice (DIO). We consider
that this secretion comes from ARH neurons though we
recognize the possibility that NPY secretion might be
due to other neuron populations within the hypothalamus.
Although previous studies have reported leptin’s regula-
tion of neuropeptide mRNA expression (Lin et al., 2000a;
Wang et al., 2002), neuropeptide mRNA expression in a
specific tissue does not necessarily correlate with the
level of protein expression or the level of neuropeptide se-
cretion. The first evidence of leptin-modulated neuropep-
tide secretion was demonstrated in primary hypothalamic
cultures (Nillni et al., 2000). Others have analyzed neuro-
peptide content of rat CSF as a secretion index (Pritchard
et al., 2003). Only a few studies address neuropeptide se-
cretion by using hypothalamic slices. Li et al. showed that
leptin treatment dose-dependently suppressed basal
AgRP and NPY release in the hypothalamus of fasted
male rats (Li et al., 2000). Recently, Breen et al. showed
that hypothalamic slices treated with leptin significantly188 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier Indecreased AgRP release after depolarization with KCl,
but revealed no change in POMC-derived peptide release
(Breen et al., 2005). Here, we directly demonstrate that
NPY/AgRP and a-MSH secretion in DIO mice is not
modulated by leptin (in all doses studied).
DIO mice have increased adiposity and high plasma
leptin concentrations, but the endogenous hyperleptine-
mia fails to curtail the progression of obesity. Moreover,
DIO mice are unresponsive to peripheral or central leptin
injection since they exhibit neither a decrease in food in-
take nor a decrease in body weight. This leptin resistance
has also been shown by others (El-Haschimi et al., 2000;
Lin et al., 2000b). Here, we specifically show leptin resis-
tance in arcuate neurons in DIOmice. While c-Fos expres-
sion is induced in arcuate neurons of control and DIO-R
mice after leptin treatment (presumably due to activation
of POMC neurons (Elias et al., 1999)), leptin treatment
does not alter c-Fos expression in arcuate neurons of
DIO mice. The best-defined signal transduction pathway
for leptin is the Janus kinase-STAT3 pathway. It is be-
lieved to be essential for mediating leptin’s effects on ho-
meostatic energy regulation (Bates et al., 2003). We show
that once DIO is established, the ability of leptin to activate
hypothalamic pStat3 signaling is also diminished. These
data are in agreement with previous work (El-Haschimi
et al., 2000; Munzberg et al., 2004). Notably, the dose of
leptin we used to produce a response caused supraphy-
siological serum leptin levels (around 40-fold abovec.
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Leptin Resistance in Arcuate Melanocortin NeuronsFigure 7. Restoration of Leptin Sensitivity after Changing from HFD to Regular Chow
(A) Body weight change of control, DIO, and restored mice at 37 weeks.
(B) Glucose tolerance in DIO and restored mice after 14 hr of fasting. Shaded region represents control group response.
(C) Body weight change (%) in control, restored, and DIO mice 24 hr after i.p. saline or leptin (2 mg/g/day).
(D) Leptin (100 nM) modulation of AgRP secretion in control, restored, and DIO groups. Data from each group normalized to baseline levels.
(E) Leptin (100 nM) modulation of NPY secretion in control, restored, and DIO groups. Data from each group normalized to baseline levels.
(F) Leptin (100 nM) modulation of a-MSH secretion in control, restored, and DIO groups. Data from each group normalized to baseline levels.
Results expressed as mean ± SEM (*p < 0.05, **p < 0.01,***p < 0.001).endogenous control levels and 5-fold above DIO levels),
suggesting that endogenous leptin signaling in the ARH
of DIO mice must be severely impaired since they are un-
responsive to such high leptin levels.
Our data does not support the hypothesis that hyperlep-
tinemia produces leptin resistance by a down-regulation
of ObRb, because ObRb mRNA expression was not
different between control and DIO mice. These results
agree with some studies in male mice and rats fed HFD
(Munzberg et al., 2004; Sahu et al., 2002; Takahashi
et al., 2002). However, other groups have shown de-
creased ObRb mRNA expression in these models (Lin
et al., 2000b; Zhang and Scarpace, 2006). We consider
that the magnitude of decreased ObRb expression,
30% when it has been shown, is probably not enoughCellto explain the leptin resistance phenotype. Sahu et al.
showed that ObRb expression in rats remained un-
changed despite adenovirus-mediated hyperleptinemia
(Sahu et al., 2002).
We tested if leptin resistance might be due to a disrup-
tion downstream of leptin receptor binding. In normal rats,
an induction of SOCS-3 (a negative regulator of leptin
signal transduction) occurs following i.p. leptin in areas
involved in body weight regulation (Bjorbaek et al.,
1998). We found higher baseline SOCS-3 mRNA levels in
the ARH of DIO mice. After i.p. leptin, only the control
mice showed an increase of SOCS-3. These results are
in agreement with others (Munzberg et al., 2004). Interest-
ingly, deletion of SOCS-3 in POMC neurons caused a re-
duction in the rate of weight gain in mice fed HFD, and theMetabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 189
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(Kievit et al., 2006). The complete lack of leptin respon-
siveness of the ARH in DIO mice seems to possibly be
due to increased SOCS-3 expression, yet cannot be
proven by our current data. Deleting SOCS-3 in another
neuronal population (e.g., AgRP) may help to provide
more evidence supporting SOCS-3 as a major cause of
leptin resistance.
To examine changes in neuropeptide expression with
leptin treatment, we exploredmajor ARH neurons involved
in energy homeostasis. In control and DIO mice, NPY,
AgRP and POMC mRNA expression were not different in
baseline conditions, as previously shown (Takahashi et al.,
2002). After leptin, NPY and AgRP mRNA expression de-
creased in control mice, but had no effect on DIO mice.
We anticipated this result, since the secretion experiment
showed decreased release only in the control mice. Many
groups have achieved similar and dissimilar results. How-
ever, all of the groups’ paradigms differed slightly from our
own (Lin et al., 2000a; Wang et al., 2002).
It is well-established that themelanocortin pathwayme-
diates some of leptin’s actions. Since a-MSH is a MC4R
agonist and AgRP is a MC4R inverse agonist, the secre-
tion ratio a-MSH/AgRP is an index of MC4R activation.
Herewe show that atmost leptin concentrations, DIOmice
have 3 times less activation of this receptor compared
with control or DIO-R mice. The DIO’s leptin resistance
prevents a leptin-induced increase of a-MSH secretion
while preventing a decrease in AgRP secretion. This leads
to weakened central melanocortin activation. We con-
firmed that the distal components of themelanocortin sys-
tem were intact. Indeed, in DIO mice the MC4R agonist
caused a prolonged effect of reduced feeding, as seen
by others (Pierroz et al., 2002). We consider that this in-
creased responsiveness is due to the observed overex-
pression of MC4R mRNA seen in the PVH of DIO mice.
While one group also showed increased expression of
MC4R in the VMH and other areas in DIO mice (Huang
et al., 2003), another group found a lower MC4R expres-
sion in DIO rats. However, the latter group demonstrated
the same response to MTII treatment as our results (Li
et al., 2004). Thus, leptin resistance leads to some type
of hypersensitivity in the melanocortin pathway in re-
sponse to pharmacological stimulation of the MC4R, at
least partially caused by an overexpression of MC4R.
This series of studies strongly suggests a primary failure
of leptin to modulate the melanocortin system in DIO
mice, and further suggests that the distal melanocortin
system remains intact and capable of regulating energy
balance.
Despite genetically identical backgrounds, some
C57BL/6J mice on HFD are able to maintain a regular
body weight—only 7% heavier than control mice. DIO-R
mice also retain the same ‘‘normal’’ response to exoge-
nous leptin and glycemic control as control mice. The abil-
ity of DIO-R mice to maintain their regular body weight is
not due to overexpression of melanocortin peptides, be-
cause there was a decrease in the biosynthesis of prohor-
mones (acetyl- and desacetyl-a-MSH, ACTH, and CLIP).190 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier IncWe found that the only predictor of DIO-R versus DIO
mice was that initial body weights (at 6 weeks of age) sig-
nificantly correlated to final body weights. Variations in lit-
ter size could have been the cause, since litter size can
have strong effects on development of adiposity (Schmidt
et al., 2000). Levin and colleagues did extensive work on
diet resistance anddiet-inducedobese animals using a se-
lective inbred strain of rats (Irani et al., 2007; Levin et al.,
1997). These rats showed pre-existing differences to lep-
tin/insulin sensitivity and other metabolic parameters be-
fore HFD exposure. We did not see such differences in
the homogenous in-bred strain of C57BL/6J mice we
used. Koza et al., however, used the same mouse model
as ours and was able to determine gene expression differ-
ences in the adipose tissue before the mice were put on
HFD. They also showed that these mice, prone to DIO,
have a stable phenotype that can be detected soon after
weaning. Furthermore, they suggest an epigenetic mech-
anism underlying the variable obesity phenotypes (Koza
et al., 2006).
DIO mice become leptin resistant and most of them be-
come diabetic. But, they can lose weight by decreasing
the fat content of their diet (Parekh et al., 1998). In our
model, the restored group lost weight by eating the
same amount of calories as the DIO group, but less fat.
The mice of Koza et al. showed the same response as
the first 2 weeks of our 7 week diet reversal (Koza et al.,
2006). This suggests that it is macronutrient composition
that causes weight gain in DIO mice and not the total cal-
ories consumed. After losing weight, the response to a
glucose challenge was normalized, as well as leptin sensi-
tivity, shown by a decrease in body weight after i.p. leptin.
Restored mice showed a re-established response to lep-
tin-regulated neuropeptide secretion. This recovery of lep-
tin sensitivity was in parallel with the recovery of NPY/
AgRP and POMC neurons’ response to leptin actions.
In summary, we determined that leptin sensitivity of
POMC and NPY/AgRP neurons in the ARH is drastically
decreased in DIO, but not in DIO-R mice. While we have
excluded the possibility that changes in ObRb expression
could be responsible for leptin resistance, the observed
upregulation of SOCS-3 supports the hypothesis that it
may be playing a key role. We demonstrated that the mel-
anocortin system downstream of the ARH in DIO mice is
over-responsive possibly due to upregulation of MC4R in
the PVH. Lastly, we demonstrated that the recovery of lep-
tin resistance is due to a recovery of NPY/AgRP andPOMC
neuronsensitivity to leptin’s actions. Thesestudiesstrongly
suggest a primary failure of leptin to modulate the melano-
cortin system in DIO mice, and further suggest that the
distal melanocortin system remains intact and capable of
regulating energy balance. These studies do not prove
that leptin resistance in the ARH is a cause of DIO, but
they strongly support the case since it is known that leptin
sensing in themelanocortin circuits is necessary for normal
energy homeostasis (Coppari et al., 2005). Our work sug-
gests that therapeutic strategies to inhibit SOCS-3, to reg-
ulate the melanocortin system, or to directly stimulate
MC4R may bypass leptin resistance in obese organisms..
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Animals: Diet and Experimental Procedures
At 6 weeks of age, C57BL/6J mice (Jackson Laboratories, Bar Harbor,
ME) were fed a regular diet (Purina Lab Chow #5001, Ralston Purina
Corp, St. Louis, MO) or a HFD (Rodent Chow #D12451, Research Diets
Inc., New Brunswick, NJ) for 20 or 37 weeks. Regular diet provided 3.3
kcal/g of energy (59.8% carbohydrate, 28.0% protein, and 12.1% fat).
HFD provided 4.75 kcal/g of energy (35.0% carbohydrate, 20.0% pro-
tein, and 45.0% fat). In seven independent experiments, mice were
housed (5/cage) in a controlled environment. Food and water were
available ad libitum unless otherwise indicated. Body weights
were measured weekly. To measure food intake, some mice were in-
dividually housed. In two experiments, groups of DIO mice that had
been on HFD for 20 weeks were then switched to regular diet for 17
weeks (until week 37). Mouse procedures were performed in accor-
dance with the guidelines and approval of the Oregon National Primate
ResearchCenter’s Institutional Animal Care andUseCommittee. Body
composition was measured using dual X-ray absortiometry (DXA)
(Lunar Piximus, GE Medical Systems, Madison, WI).
Radioimmunoassay
a-MSH immunoreactivity was measured with a rabbit anti-a-MSH
(Phoenix Pharmaceuticals, Inc., Belmont, CA). The antibody cross-
reacts fully with the acetylated a-MSH and partially (46%) with desace-
tylated a-MSH, but not with NPY nor AgRP. NPY immunoreactivity was
measured with a rabbit anti-NPY (kindly provided by Dr. Williams, Uni-
versity of Liverpool, UK). The antibody does not crossreact with AgRP
nor a-MSH (King et al., 2000). AgRP immunoreactivity was measured
with a rabbit anti-AgRP (82-131)-NH2 (Phoenix Pharmaceuticals,
Inc., Belmont, CA). The antibody does not crossreact with a-MSH
nor NPY. 125I-labeled a-MSH, AgRP, and NPY were prepared by the
iodogen method and purified by high-pressure liquid chromatography
(a-MSH and NPY) or by AG1X8 ion exchange resin (AgRP) (University
of Mississippi Peptide Radioiodination Service Center, University,
MS). For the a-MSH RIA, the lowest detectable level (LDL) that could
be distinguished from the zero standard was 0.30 fmol/tube. The intra-
assay variation (CV%1) was determined by replicate analysis (n = 10) of
two samples at a-MSH concentrations of 2 and 10 fmol/tube, and the
results were 7.8% and 7.5%, respectively. The inter assay-variation
(CV%2) was 10.7% and 12.1% for the range of value measured. For
NPY, the LDL was 0.32 fmol/tube. The CV%1 was determined by rep-
licate analysis (n = 10) of one sample at a NPY concentration of 5 fmol/
tube and the result was 9.1%. The CV%2 was 11.1%. For AgRP, the
LDL was 0.70 fmol/tube. The CV%1 was determined by replicate anal-
ysis (n = 10) of two samples at AgRP concentrations of 2 and 10 fmol/
tube, and the results were 9.1% and 9.8%, respectively. The CV%2
was 13.4% and 13.5% for the range of values measured.
Intraperitoneal Leptin in Mice before and after 20 or 37 Weeks
on HFD
Mice (28 control, 10 DIO-R, and 10 DIO) were individually housed and
sham injected for 5 days prior to drug treatment. Mice were divided
into two groups which received intraperitoneal (i.p.) injections of re-
combinant murine leptin (Peprotech, 2.0 mg/g body weight) or saline
for 2 days. Body weights and calorie intake were measured daily.
IntraperitonealMelanotan-II inMice after 20 or 37Weeks onHFD
Mice (8 control, 8 DIO-R, and 8 DIO) were individually housed and
fasted overnight. Following 5 days of daily sham injection, half of the
mice received i.p. melanotan-II (MTII) (NeoMPS Inc., San Diego, CA,
1.0 mg/g) and the other half received i.p. saline. Fifteen minutes after
the injection, food was reoffered. Food intake was measured during
24 hr after the injection.CellIntracerebroventricular Leptin/MTII in Mice after 20 Weeks
on HFD
Under isoflurane anesthesia, a sterile guide cannula (15 mm long, 22
gauge, Plastics One, Inc. Roanoke, VA) was stereotaxically implanted
into the lateral ventricle (-0.5 mm posterior, 1 mm lateral to bregma,
and 1.5 mm below the surface of the skull, in accordance with Franklin
and Paxinos [Paxinos and Franklin, 2001]) of control, DIO-R, and DIO
mice. A 28-gauge obturator was inserted into each cannula. Cannula
position was verified at the end of the experiment by dye administra-
tion and histological analysis. After 2 weeks, mice received intracer-
ebroventricular (i.c.v.) leptin (0.1 mg) or aCSF in 1 ml. In one experiment,
food intake and body weight were measured after 24 hr. Two days
later, experimental treatments were crossed over in all mice. In another
experiment,micewere perfused 45min after i.c.v. leptin administration
for IHC.
Eight naı¨vemice were given increasing doses ofMTII i.c.v. (0.01–500
ng). The minimum dose that produced significant modification of food
intake in control mice (0.1 ng) was selected for the follow-up experi-
ment. Mice (control, DIO-R, and DIO) were divided into two groups,
each receiving i.c.v. MTII or aCSF after an overnight fast. Food intake
was recorded during 24 hr after the injection.
Static Incubation of Hypothalamic Explants after 20 or 37Weeks
on HFD
After 20 weeks on regular or HFD diet, in five duplicate experiments,
620 mice were sacrificed by decapitation and whole brains immedi-
ately removed. The hypothalamus was cut from the rest of the brain.
Care was taken to ensure that there was no contamination of the hypo-
thalamic portion with residual pituitary. A 2 mm thick slice of medio-
basal forebrain was prepared using a vibrating microtome (Leica VS
1000, Leica Microsystems, Inc., Bannockburn, IL). Each slice was
taken from the base of the brain to include the PVH and ARH. Hypo-
thalami were treated separately with aCSF (w/0.6 TIU aprotinin/ml),
equilibrated with 95% O2 and 5% CO2 and incubated at 37
C. After a
1 hr equilibration period, hypothalami were incubated for 45 min in
aCSF (basal period) before being challenged with a single concentra-
tion of leptin (0.1 to 100 nM) for 45 min. Tissue viability was verified by
exposure to 56mMKCl for 45min. Each experiment was repeated four
times. Treatments were performed in quadruplicate. At the end of each
period, supernatants were removed and frozen until assayed. Hypo-
thalamic explants that failed to show peptide release 3X above that
of basal in response to KCl were excluded from analysis.
Immunohistochemical Studies after 20 Weeks on HFD
Mice (8 control, 8 DIO-R, and 9 DIO) were injected i.p. with 2 mg/g leptin
or saline. After 30min, mice were killed under pentobarbital anesthesia
by cardiac perfusion with PBS then paraformaldehyde in NaPO4 buffer
(pH 7.4). Brainswere removed, dehydrated in 25%sucrose, frozen and
stored at80C until sectioned coronally on a microtome (30 mm). For
pStat3 and pMAPK immunohistochemical (IHC), free-floating tissue
was pretreated in 1%NaOH+1%H2O2 in H2O for 10min, 0.3% glycine
for 10 min, 0.03% SDS for 10 min, and blocked in 3% NDS in PBS/
0.25% Triton X-100/0.02%NaN3. For c-Fos IHC, tissue was incubated
in blocking buffer for 20 min (KPBS+0.4% Triton X-100 + 2% donkey
serum) to reduce background. Antibodies (Phospho-Stat3 rabbit
#9135, 1:1000, Phospho-p44/42 Map Kinase rabbit #9101, 1:1000,
Cell Signaling Technology, Beverly, MA; c-Fos rabbit #SC-52,
1:10000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added
in blocking solution and incubated overnight at room temp. Sections
were washed, incubated with Biotin-SP-conjugated AffiniPure F(ab1)2
Fragment Donkey Anti-Rabbit IgG secondary antibody (Jackson Im-
munoResearch Laboratories, West Grove, PA) 1:1000 in blocking so-
lution, without NaN3, for 1 hr. Tissue was treated with Vectastain Elite
ABC Kit (Vector Labs, Burlingame, CA) for 1 hr, and the signal devel-
oped by NiSO4/DAB solution. Tissue was mounted on subbed slides,
cover slipped, and photographed.Metabolism 5, 181–194, March 2007 ª2007 Elsevier Inc. 191
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Mice (23 control, 21 DIO-R, and 22 DIO) were injected i.p. with 2 mg/g
leptin or saline. After 2 hr, mice were killed and brains were frozen on
dry ice. In situ hybridization (ISH) was performed as previously de-
scribed (Grove et al., 2001). Six riboprobes were transcribed from
cDNA as follows: rat NPY cRNA (400 bp) and rat POMC cRNA (925
bp), in which 25% of the UTP was 35S-labeled, and mouse AgRP
cRNA (807 bp), rat leptin receptor (ObRb) cRNA (400 bp), mouse
MC4R cRNA (520 bp) and SOCS-3 cRNA (450 bp) in which 100%
of the UTP was 33P-labeled (AgRP, ObRb, MC4R, and SOCS-3 cDNAs
were all kind gifts from the Elmquist Lab). Tissue was incubated in anti-
sense probe (20million counts perml labeled probe) overnight at 55C.
Tissue was then washed in SSC, RNase A at 37C, then 0.1x SSC at
55-60C. Tissue was dehydrated and exposed to autoradiographic
film for 1–8 days then dipped in Kodak NBT2 emulsion and stored in
light-tight boxes for 7–60 days. Slides were developed and counter-
stained with cresyl violet. A CoolSnap HQ camera (Photometrics,
Westchester, PA) coupled with Metamorph Software (Universal Imag-
ing Corp) was used to quantify autoradiograms. The area of exposed
film and the average gray level density of labeling (integrated OD) in
each region studied weremeasured using a constant sampling box en-
compassing the entire labeled area. Background labeling was sub-
tracted from OD values. For the PVH and ARH measurements, the
sampling box encompassed the entire nucleus, except for the
SOCS-3 sampling box which contained 1 hemisphere of the ARH.
Mean integrated OD for each brain region was obtained from sections
that were anatomically matched between mice.
Microdissection and Real-Time PCR after 20 Weeks on HFD
Mice (14 control and 14 DIO) were injected i.p. with 2 mg/g leptin or sa-
line. After 45 min, mice were anesthetized and brains were rapidly re-
moved. The hypothalamus was cut from the rest of the brain. 0.4 mm-
slices were prepared in aCSF using a vibrating microtome and then
placed in RNAlater (Ambion, Austin, TX). Using a dissecting micro-
scope, the ARH and PVHwere cut from each slice using the fornix, op-
tic tracts, and third ventricle as landmarks. ARH and PVH pieces were
then put into separate microcentrifuge tubes and stored at80C. To-
tal RNAwas isolated from each sample usingQiagen’s RNeasyMini Kit
(Valencia, CA). Standard RT-PCR was performed using 0.1 mg of total
RNA. Samples were bioanalyzed on a RNA 6000 Nano chip kit (Agilent
2100 Bioanalyzer, Agilent Technologies, Inc., Palo Alto, CA) to check
for integrity and concentration. Real-time PCR was performed on the
ABI 7900HT (Applied Biosystems Foster City, CA) using the SOCS-3
and MC4R primer/probe set (cat. #mm00545913 s1, #mm 00457483
s1, ABI) for 45 cycles and using 18S as an internal control.
Glucose/Insulin Tolerance Tests after 20 or 37 Weeks on HFD
After a 14 hr fast, samples were obtained in the morning from saphe-
nous vein bleeds. Blood glucose was measured using a glucometer
(Accu-chek, Roche Diagnostic Corporation, Indianapolis, IN) at 0, 15,
30, 60 and 120 min after an i.p. injection of glucose (1 mg/g). Samples
(30 ml of blood) were obtained at each time point to check for insulin
levels by RIA (Linco Research Inc). For the insulin tolerance test
(ITT), blood glucose measurements were taken at 0, 15, and 30 min
after injection of human insulin (1.0 U/kg; Lilly, Indianapolis, IN).
HPLC Fractionation and RIA
The hypothalami, in acetic acid supplementedwith a protease inhibitor,
were heated at 95C for 15min, sonicated, and cell disruption was per-
formedusingaDouncehomogenizer. Sampleswere thencentrifugedat
15000rpm at 4C for 30 min. Finally, supernatants were collected and
proteinconcentrationsweredeterminedbyBradfordassay (Coomassie
Protein Assay Reagent, Pierce. Rockford, IL, USA). Supernatants were
then evaporated using a speed vacuum and reconstituted in 1 ml of
0.1% trifluoracetic acid (TFA) solution. 200 mg of total protein was in-
jected into a Varian ProStar Gradient HPLC System equipped with
a C18 reverse phase column (Microsorb MV 300-5; Varian Inc. Palo
Alto, CA, USA) used to fractionate the tissue samples. For POMC-192 Cell Metabolism 5, 181–194, March 2007 ª2007 Elsevier Incderivate peptide elution, a linear gradient was used from 20%–40% B
in 20 min using the following mobile phases: (A) 0% acetonitrile/0.1%
TFA and (B) 100% acetonitrile/0.1% TFA. The flow rate was 1.5 ml/
min and there were equilibration times used on either side of the gradi-
ent. Fractions (0.75 ml) were collected over the entire 20 min gradient.
These fractions were then evaporated using a speed vacuum and re-
constituted in buffer used for RIA. Synthetic peptides were injected
on the HPLC to determine retention times. Predicted retention times al-
lowed for analysis of specific regionsalong thegradient forRIAanalysis.
The assays used for a-MSH and ACTH-derived peptides were de-
veloped in our laboratory (E.N.) using commercially available peptides
and primary antibodies. Each purified peptide was iodinated with 125I
using the Chloramine T oxidation-reduction method, purified by
HPLC, and used as tracer. The a-MSH RIA was performed in 0.5 ml
of phosphate buffer (pH 7.4)/500 mg/liter sodium azide/2.5 g/liter
BSA, with primary anti-a-MSH antiserum (1:20,000), and 5000 cpm
of 125I des-aMSH tracer. The sensitivity of the assays was approxi-
mately 11.5 pg/tube, and the intra- and interassay variability were ap-
proximately 5%–7% and 10%–11%, respectively. The a-MSH assay
used in this condition can detect both acetyl- and des-a-MSH forms.
The ACTH RIA was also performed in 0.5 ml of the same RIA buffer
by using the anti-ACTH antiserum (1:30,000) and 5000 cpm of 125I-
ACTH tracer. The sensitivity of the assays was approximately 10.0
pg/tube, and the intra- and interassay variability were approximately
5%–7% and 10%–11%, respectively.
Statistical Analysis
All values are expressed as mean ± SEM. Data were analyzed by two-
way analysis of variance (ANOVA) for body weight change over time,
calorie intake over time, i.p./i.c.v leptin effect on food intake, body
weight, mRNA expression, IHC cell counts, and i.p./i.c.v. MTII effect
on food intake. One-way ANOVAwas used for final body weights, total
calorie intake, feeding efficiency, blood leptin levels, and leptin sensi-
tivity, followed by Bonferroni’s Multiple Comparison Test. Body weight
change correlation was analyzed using linear regression test. Secre-
tion experiments were analyzed using Nonlinear Regression (sigmoidal
dose-response best-fit curve). Data for the bimodal distribution was
assessed by the D’Agostino & Pearson omnibus normality test. For
glucose and insulin tolerance tests, areas under the curve (AUC)
were calculated by trapezoid analysis and were compared by one-
way ANOVA. Probability values < 0.05 were considered statistically
significant. Analyses were performed with statistical software (Graph-
Pad Prism 4.0, GraphPad Software, Inc., San Diego, CA).
Supplemental Data
Supplemental Data include three figures and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/5/3/
181/DC1/.
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